Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding Co's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$982 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$2,268 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Giant Biogene Holding Co's annualizedROC % for the quarter that ended in Dec. 2025 was 47.73%.
Giant Biogene Holding Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 136.07%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Giant Biogene Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.21%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Giant Biogene Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co (HKSE:02367) has a EBIT of HK$2,268 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Giant Biogene Holding Co.
Is Giant Biogene Holding Co's EBIT too high?
Giant Biogene Holding Co's current EBIT is HK$2,268 Mil. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's EBIT compare to PG and CL?
Giant Biogene Holding Co's EBIT of HK$2,268 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Giant Biogene Holding Co. Giant Biogene Holding Co's current EBIT is HK$2,268 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.00, compared to a current price of HK$24.28 — trading 64.3% below its estimated fair value. The current EBIT is HK$2,268 Mil. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current EBIT is HK$2,268 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.28 is trading 64.3% below its estimated GF Value™ of HK$68.00.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
EBIT: HK$2,268 Mil
GF Value™: HK$68.00 vs. price of HK$24.28 (64.3% below fair value)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
